68Ga-PSMA-11(HBED-CC)PET/CT在复发性前列腺癌患者中的诊断效能:1007例患者评估
该研究回顾性分析2014年1月至2017年1月间1007例连续接受68Ga-PSMA-11 PET/CT(注射后1小时)扫描以检测复发灶的患者,评估PSA水平、PSA倍增时间、PSA速率、Gleason评分、持续雄激素剥夺治疗、年龄及注射活度等变量对PSMA摄取的影响。79.5%患者至少检测到一处提示复发的病灶,阳性PET/CT与PSA水平和ADT相关,而GSC、注射活度、年龄、PSADT和PSAVel在多变量分析中与阳性扫描无关联。
要点
- 79.5%的复发性前列腺癌患者经68Ga-PSMA-11 PET/CT检测到至少一处提示复发的病灶。
- 阳性PET/CT扫描与PSA水平及持续雄激素剥夺治疗(ADT)相关。
- GSC、注射活度、年龄、PSADT和PSAVel在多变量分析中与阳性PET/CT无关联。
核心结论
- 68Ga-PSMA-11 PET/CT在较高比例的复发性前列腺癌患者中检测到肿瘤病灶。
- 肿瘤检出与PSA水平和ADT明确相关。
- 较高的GSC与较高的阳性PET/CT概率之间仅存在无统计学显著性的趋势。
- 阳性68Ga-PSMA-11 PET/CT扫描与患者年龄、注射活度、PSADT或PSAVel之间未发现关联。
研究设计与样本
- 回顾性分析2014年1月至2017年1月间1007例连续接受68Ga-PSMA-11 PET/CT(注射后1小时)扫描以检测复发灶的患者。
- 排除未经治疗的初诊前列腺癌患者或转诊接受PSMA放射配体治疗的患者。
- 评估变量包括PSA水平、PSA倍增时间(PSADT)、PSA速率(PSAVel)、Gleason评分(GSC,含GSC 7a和7b的单独分析)、持续雄激素剥夺治疗(ADT)、患者年龄及注射活度。
主要发现
- 79.5%的患者至少检测到一处具有提示复发性前列腺癌特征的病灶。
- 病理性(阳性)PET/CT扫描与PSA水平和ADT相关。
- 多变量分析中GSC、注射活度、患者年龄、PSADT和PSAVel与阳性PET/CT扫描无关联。
- 较高的GSC与较高的病理性PET/CT扫描概率之间仅存在无统计学显著性的趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Since the clinical introduction of 68Ga-PSMA-11 PET/CT, this imaging method has rapidly spread and is now regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). The aim of this study was to analyse the influence of several variables with possible influence on PSMA ligand uptake in a large cohort. METHODS: We performed a retrospective analysis of 1007 consecutive patients who were scanned with 68Ga-PSMA-11 PET/CT (1 h after injection) from January 2014 to January 2017 to detect recurrent disease. Patients with untreated primary PCa or patients referred for PSMA radioligand therapy were excluded. The possible effects of different variables including PSA level and PSA doubling time (PSADT), PSA velocity (PSAVel), Gleason score (GSC, including separate analysis of GSC 7a and 7b), ongoing androgen deprivation therapy (ADT), patient age and amount of injected activity were evaluated. RESULTS: In 79.5% of patients at least one lesion with characteristics suggestive of recurrent PCa was detected. A pathological (positive) PET/CT scan was associated with PSA level and ADT. GSC, amount of injected activity, patient age, PSADT and PSAVel were not associated with a positive PET/CT scan in multivariate analysis. CONCLUSION: 68Ga-PSMA-11 PET/CT detects tumour lesions in a high percentage of patients with recurrent PCa. Tumour detection is clearly associated with PSA level and ADT. Only a tendency for an association without statistical significance was found between higher GSC and a higher probability of a pathological PET/CT scan. No associations were found between a pathological 68Ga-PSMA-11 PET/CT scan and patient age, amount of injected activity, PSADT or PSAVel.
引用
- Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017. PMID: 28497198. doi:10.1007/s00259-017-3711-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。